TT 701

Drug Profile

TT 701

Alternative Names: LY 2452473; OPK 88004

Latest Information Update: 14 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Developer Brigham and Women's Hospital; Dana-Farber Cancer Institute; Transition Therapeutics
  • Class Erectile dysfunction therapies
  • Mechanism of Action Selective androgen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Erectile dysfunction; Prostate cancer

Most Recent Events

  • 01 Mar 2017 Transition Therapeutics plans a phase II trial for Benign prostatic hypertrophy in 2H 2017
  • 31 Aug 2016 Transition Therapeutics has been acquired by OPKO Health
  • 01 Apr 2016 Phase-II clinical trials in Prostate cancer in USA (PO) (NCT02499497)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top